VEGFA and glioblastoma: Another important GBM treatment approach is the anti-vascular endothelial growth factor antibody bevacizumab with antiangiogenic properties; it received accelerated approval from the Food and Drug Administration (FDA) in 2009 as a single agent for progressive GBM following prior therapy [37].